Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/23000
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2021-12-06T08:19:06Z-
dc.date.available2021-12-06T08:19:06Z-
dc.date.issued2009-04-
dc.identifier.citationKeskin, M. vd. (2009). "Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: Relation to disease severity". Internal Medicine Journal, 39(4), 243-248.en_US
dc.identifier.issn1444-0903-
dc.identifier.issn1445-5994-
dc.identifier.urihttps://doi.org/10.1111/j.1445-5994.2009.01793.x-
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/j.1445-5994.2009.01793.x-
dc.identifier.urihttp://hdl.handle.net/11452/23000-
dc.description.abstractBackground: It has been recently reported that serum paraoxonase (PON1) and arylesterase (ARE) activities may be significantly reduced in patients with chronic liver disease. The aim of the study was to investigate the relations between serum PON1 and ARE activities and the degree of liver damage in patients with chronic liver injury. Methods: We studied a total of 75 patients with chronic liver disease (50 patients with cirrhosis and 25 patients with chronic hepatitis) and 25 healthy comparison subjects. Baseline and salt-stimulated PON1 and ARE activities were determined in all study participants. Results: Baseline and stimulated PON1 and ARE activities were significantly lower in patients with chronic liver disease than in controls. Cirrhotic patients in Child-Pugh classes B and C subgroups had significantly reduced PON1 and ARE activities compared with Child-Pugh class A patients (both P-values < 0.01). Receiver operating characteristic curve analysis showed that serum ARE activity was the most effic Conclusion: Baseline and stimulated PON1 and ARE activities are reduced in patients with chronic liver disease. Serum ARE activity could be a suitable biomarker for the evaluation of the presence and severity of chronic liver damage.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectArylesteraseen_US
dc.subjectChronic liver diseaseen_US
dc.subjectCirrhosisen_US
dc.subjectLiver function testsen_US
dc.subjectParaoxonaseen_US
dc.subjectUremic patientsen_US
dc.subjectSerumen_US
dc.subjectPolymorphismen_US
dc.subjectCirrhosisen_US
dc.subjectDamageen_US
dc.subjectGeneral & internal medicineen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAlanine transaminaseen_US
dc.subject.meshApolipoprotein A-Ien_US
dc.subject.meshAryldialkylphosphataseen_US
dc.subject.meshAspartate aminotransferasesen_US
dc.subject.meshBilirubinen_US
dc.subject.meshBiological markersen_US
dc.subject.meshCarboxylic ester hydrolasesen_US
dc.subject.meshCholesterolen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B, chronicen_US
dc.subject.meshHepatitis C, chronicen_US
dc.subject.meshHumansen_US
dc.subject.meshLiver cirrhosisen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPhenotypeen_US
dc.subject.meshROC curveen_US
dc.subject.meshSeverity of illness indexen_US
dc.subject.meshSodium chlorideen_US
dc.subject.meshStimulation, chemicalen_US
dc.subject.meshTriglyceridesen_US
dc.titleBaseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: Relation to disease severityen_US
dc.typeArticleen_US
dc.identifier.wos000265426600006tr_TR
dc.identifier.scopus2-s2.0-65349098761tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0003-4518-5283tr_TR
dc.contributor.orcid0000-0002-3208-6211tr_TR
dc.contributor.orcid0000-0003-4526-4352tr_TR
dc.identifier.startpage243tr_TR
dc.identifier.endpage248tr_TR
dc.identifier.volume39tr_TR
dc.identifier.issue4tr_TR
dc.relation.journalInternal Medicine Journalen_US
dc.contributor.buuauthorKeskin, Murat-
dc.contributor.buuauthorDolar, Engin-
dc.contributor.buuauthorDirican, Melahat-
dc.contributor.buuauthorKıyıcı, Murat-
dc.contributor.buuauthorYılmaz, Yusuf-
dc.contributor.buuauthorGürel, Selim-
dc.contributor.buuauthorNak, Selim Giray-
dc.contributor.buuauthorGülten, Macit-
dc.contributor.buuauthorErdinç, Selda-
dc.contributor.researcheridAAI-4213-2021tr_TR
dc.contributor.researcheridAAG-9177-2021tr_TR
dc.contributor.researcheridAAG-6985-2021tr_TR
dc.identifier.pubmed19402863tr_TR
dc.subject.wosMedicine, general & internalen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubmeden_US
dc.wos.quartileQ2en_US
dc.contributor.scopusid23050640000tr_TR
dc.contributor.scopusid6602075084tr_TR
dc.contributor.scopusid6601919847tr_TR
dc.contributor.scopusid6507627491tr_TR
dc.contributor.scopusid22936014300tr_TR
dc.contributor.scopusid7003706434tr_TR
dc.contributor.scopusid6603336505tr_TR
dc.contributor.scopusid6603629209tr_TR
dc.contributor.scopusid24334883200tr_TR
dc.subject.scopusAryldialkylphosphatase; Arylesterase; Human PON1 Proteinen_US
dc.subject.emtreeAryldialkylphosphataseen_US
dc.subject.emtreeArylesteraseen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeChronic hepatitisen_US
dc.subject.emtreeChronic liver diseaseen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeEnzyme activityen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLiver injuryen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeReceiver operating characteristicen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.